Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma
暂无分享,去创建一个
B. Fridley | E. Goode | J. Cunningham | S. Gayther | Chen Wang | S. Weroha | K. Lawrenson | S. Winham | Junqiang Dai | Rama Raghavan | Qian Li | X. Hou | K. Kalli
[1] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[2] A. Buja,et al. Remarks on Parallel Analysis. , 1992, Multivariate behavioral research.
[3] Adrian E. Raftery,et al. Model-based clustering and data transformations for gene expression data , 2001, Bioinform..
[4] Kathleen R. Cho,et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.
[5] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Boyd,et al. Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.
[7] D. Huo,et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. , 2006, Cancer research.
[8] Kathleen R. Cho,et al. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.
[9] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[10] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[11] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[12] S. Plaxe. Epidemiology of low-grade serous ovarian cancer. , 2008, American journal of obstetrics and gynecology.
[13] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[14] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[15] W. Weichert,et al. A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.
[16] Kathleen R. Cho,et al. IRS1 Regulation by Wnt/β-Catenin Signaling and Varied Contribution of IRS1 to the Neoplastic Phenotype , 2009, The Journal of Biological Chemistry.
[17] A. Whittemore,et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.
[18] A. Whittemore,et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.
[19] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[20] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[21] W. McCluggage,et al. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.
[22] J. Leek. Asymptotic Conditional Singular Value Decomposition for High‐Dimensional Genomic Data , 2011, Biometrics.
[23] O. Mariani,et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response , 2011, Nature Medicine.
[24] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[25] Jae K. Lee,et al. Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance , 2012, PloS one.
[26] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[27] Sebastian M. Armasu,et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer , 2013, Nature Communications.
[28] Benjamin Haibe-Kains,et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.
[29] R. Albulescu. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. , 2013, Biomarkers in medicine.
[30] K. Cibulskis,et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.
[31] B. Schittek,et al. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis , 2014, Molecular Cancer.
[32] E. Goode,et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.
[33] Y-H Wu,et al. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer , 2014, Oncogene.
[34] Benjamin Frederick Ganzfried,et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. , 2014, Journal of the National Cancer Institute.
[35] Eugenia G. Giannopoulou,et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells , 2014, Oncogene.
[36] C. Huttenhower,et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. , 2014, Journal of the National Cancer Institute.
[37] B. Karlan,et al. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. , 2014, Gynecologic oncology.
[38] C. Wijmenga,et al. Gene expression analysis identifies global gene dosage sensitivity in cancer , 2015, Nature Genetics.
[39] Kconfab Investigators,et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015 .
[40] M. Dietel,et al. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. , 2015, Anticancer research.
[41] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[42] Yurii B. Shvetsov,et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015, Nature Genetics.
[43] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[44] I. Shih,et al. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. , 2016, The American journal of pathology.
[45] B. Karlan,et al. "Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine. , 2016, Gynecologic oncology.
[46] T. Ørntoft,et al. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells , 2016, Nature communications.
[47] Z. Dong,et al. PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model , 2016, Oncogene.